Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25042092 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Moustafa S Ghanem und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Niacin. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, the Breast Cancer Research Pro-875 gram (U.S. Department of Defense), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie.
Abstract (Originalsprache)
The addiction of tumors to elevated nicotinamide adenine dinucleotide (NAD+) levels is a hallmark of cancer metabolism. Obstructing NAD+ biosynthesis in tumors is a new and promising antineoplastic strategy. Inhibitors developed against nicotinamide phosphoribosyltransferase (NAMPT), the main enzyme in NAD+ production from nicotinamide, elicited robust anticancer activity in preclinical models but not in patients, implying that other NAD+-biosynthetic pathways are also active in tumors and provide sufficient NAD+ amounts despite NAMPT obstruction. Recent studies show that NAD+ biosynthesis through the so-called “Preiss-Handler (PH) pathway”, which utilizes nicotinate as a precursor, actively operates in many tumors and accounts for tumor resistance to NAMPT inhibitors. The PH pathway consists of three sequential enzymatic steps that are catalyzed by nicotinate phosphoribosyltransferase (NAPRT), nicotinamide mononucleotide adenylyltransferases (NMNATs), and NAD+ synthetase (NADSYN1). Here, we focus on these enzymes as emerging targets in cancer drug discovery, summarizing their reported inhibitors and describing their current or potential exploitation as anticancer agents. Finally, we also focus on additional NAD+-producing enzymes acting in alternative NAD+-producing routes that could also be relevant in tumors and thus become viable targets for drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy.
- Ospedale Policlinico San Martino IRCCS, Largo Rosanna Benzi 10, 16132 Genova, Italy.
ORCID-Profile: Irene Caffa
Förderung
- Italian Association for Cancer Research
- the Breast Cancer Research Pro-875 gram (U.S. Department of Defense)
- the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- MFAG
- Breast Cancer Research Program (U.S. Department of Defense)
- European Union’s Horizon 2020 research and innovation programme
Zitieren
APA
Ghanem, M. S., Caffa, I., Monacelli, F., & Nencioni, A. (2024). Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042092
Vancouver
Ghanem MS, Caffa I, Monacelli F, Nencioni A. Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042092
BibTeX
@article{Ghanem2024,
author = {Ghanem, Moustafa S and Caffa, Irene and Monacelli, Fiammetta and Nencioni, Alessio},
title = {Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25042092}
}
EUVIMED